GlassScriptPhysician profile
Bernard W Taylor
NPI 1205878345
$28,312.09
in general payments reported to CMS, 2019-2025
29 companies · $622 in 2025
The $622 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,014 · 2020: $14K · 2021: $2,751 · 2022: $857 · 2023: $3,081 · 2024: $461 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,292 · Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,292.00 |
| Food and Beverage | $1,871.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Isoray, INC | $21,044.98 | 2019-2023 | Brachytherapy Source |
| Bayer Healthcare Pharmaceuticals INC. | $5,526.25 | 2019-2024 | |
| Bioprotect Medical, INC. | $218.85 | 2024-2025 | Bioprotect Balloon Implant System |
| Varian Medical Systems, INC. | $193.33 | 2019-2020 | |
| Theragenics Corporation | $136.55 | 2025 | |
| Janssen Biotech, INC. | $131.10 | 2019-2021 | |
| Novocure INC. | $116.85 | 2020-2025 | Optune, Optune Lua (Novottf-200t) |
| Bard Peripheral Vascular, INC. | $113.09 | 2023 | Model 200 Theraseed Palladium-103 In Readylink |
| Pfizer INC. | $100.94 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $91.75 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $88.87 | 2023-2025 | Libtayo |
| Elekta, INC. | $71.01 | 2019-2020 | |
| Abbvie INC. | $65.18 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.33 | 2023-2025 | Imjudo, Imfinzi |
| Blue Earth Diagnostics | $42.87 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $42.57 | 2023-2025 | |
| Visionrt, INC. | $39.28 | 2020 | |
| Incyte Corporation | $38.94 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Aveo Pharmaceuticals, INC. | $36.14 | 2024-2025 | |
| Teleflex LLC | $32.50 | 2025 | Barrigel |
| Boston Scientific Corporation | $20.50 | 2024 | Spaceoar Vue System - 10ml |
| Merck Sharp & Dohme LLC | $20.34 | 2025 | Keytruda |
| Sirtex Medical INC | $14.71 | 2024 | Sir-Spheres Microspheres |
| Caris Mpi, INC. | $14.70 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $14.63 | 2025 | |
| Lilly USA, LLC | $13.67 | 2023 | Jaypirca, Verzenio |
| Epizyme, INC. | $12.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Analogic Corporation | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.